UPSTREAM
29.1.2020 18:57:04 CET | Business Wire | Press release
93 percent of total mobile transactions in 20 countries were blocked as fraudulent in 2019 according to a report on the state of malware and mobile ad fraud released today by mobile technology company, Upstream . The “Invisible Digital Threat ” data is based on deployments of Upstream’s Secure-D full-stack anti-fraud platform that detects and blocks fraudulent mobile transactions mostly originated from ad fraud malware. The platform at the end of 2019 covered 31 mobile operators in 20 countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200129005647/en/
In the markets examined, Upstream’s security platform processed 1.71 billion mobile transactions and blocked 1.6 billion of them as fraudulent , a staggering 93 percent of total transactions . It is estimated that left unchecked these transactions would have cost users $2.1bn in unwanted charges . For the industry as a whole, losses from online, mobile and in-app advertising reached $42 billion in 2019 and are expected to reach $100 billion by 20231 .
The number of malicious apps discovered by Secure-D in 2019 rose to 98,000 , up from 63K in 2018. These 98,000 malicious apps had infected 43 million Android devices .
With Android devices now accounting for an estimate 75-85% of all smartphone sales worldwide2 Android is by far the most dominant mobile operating system (OS). At the same time it is the most vulnerable due to its open nature, making it a favorite playground for fraudsters.
While, as mentioned in the Secure-D report, it is always a good rule of thumb for consumers to only download mobile applications from Google’s official storefront, Google Play, thanks to its scale and set up, rogue apps are still getting through its defences. Of the top 100 most active malicious apps that were blocked in 2019, 32 percent are reported still available to download on Google Play . A further 19 percent of the worst-offending apps were previously on Google Play but have since been removed, while the remaining 49 percent are available through third-party app stores.
Fraudsters appear to target some app categories more than others. Ironically, apps designed to make a device function better and make everyday life easier are the ones most likely to be harmful with 22.32 percent of malicious apps for 2019 falling under the Tools / Personalization / Productivity category 3 globally. The next most popular categories cybercriminals target are Games (18.97 percent) and Entertainment/Shopping (15.76 percent).
Indicating scale, in the course of only a few months in 2019, Secure-D reported on the suspicious background activity of five very popular Android apps: 4shared, a popular file-sharing app, Vidmate, a video downloader, Weather Forecast a preinstalled app on Alcatel devices, Snaptube, another video and audio app, and ai.type, an on-screen keyboard app. With a total of nearly 700 million downloads, these were or had been at some point available on Google Play. In these five cases alone, Secure-D detected and blocked 353 million suspicious mobile transactions preventing $430 million in fraudulent charges.
Dimitris Maniatis, CEO of Upstream commented, "Mobile ad fraud is a criminal enterprise on a massive scale. Though it may seem that it is only targeted at advertisers, it greatly affects the whole mobile ecosystem. Most importantly it adversely impacts consumers; eating up their data allowance, bringing unwanted charges, messing with the performance of their device, and even targeting and collecting their personal data. It is more than an invisible threat, it is an epidemic, calling for increased mobile security that urgently needs to rise up in the industry’s priority list. Left unchecked, ad fraud will choke mobile advertising, erode trust in operators and lead to higher tariffs for users" .
The effects of mobile ad fraud are particularly damaging in emerging markets where data costs are significantly higher. As evidenced from detailed data presented from five such markets including Brazil and South Africa fraud rates in most cases exceed the 90% mark. As Upstream’s report highlights consumers in emerging markets are more vulnerable to digital fraud; they are unaware of the dangers as they often go online for the first time via their mobile devices and data depletion caused by malware has a much greater effect on them due to the high cost of data in their countries. In Africa 1 GB of data costs prepaid mobile subscribers the equivalent of 16 hours of work at minimum wage.
Download the full report for an in-depth look at the state and workings of mobile ad fraud including insights on five emerging markets: Brazil, Egypt, Indonesia, South Africa and Ethiopia . By way of comparison, the report also juxtaposes snapshots of the state of malware in the United Kingdom and USA.
-ENDS-
1 Juniper Research
2 Statista and Statcounter
3 As these categories are Google Play Store specific, percentages apply only to apps currently or previously available on Google Play
View source version on businesswire.com: https://www.businesswire.com/news/home/20200129005647/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
